Repeated influenza vaccination provides cumulative protection from distinct H3N2 viruses

Kavian, Niloufar; Hachim, Asmaa; Cowling, Benjamin J.

doi:10.1002/cti2.1297

Cited by 10 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ferritin is a SANP composed of 24 identical subunits with robust thermal and chemical stability [20]. Currently, our group has displayed various antigens on the surface of ferritin NPs related to many infectious diseases, such as influenza, acquired immunodeficiency syndrome, and canine distemper [21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice

et al. 2022

View full text Add to dashboard Cite

Currently, the incorporation of multiple epitopes into vaccines is more desirable than the incorporation of a single antigen for universal influenza vaccine development. However, epitopes induce poor immune responses. Although the use of adjuvants can overcome this obstacle, it may raise new problems. Effective antigen delivery vehicles that can function as both antigen carriers and intrinsic adjuvants are highly desired for vaccine development. Here, we report a biepitope nanovaccine that provides complete protection in mice against H3N2 virus as well as partial protection against H1N1 virus. This vaccine (3MCD-f) consists of two conserved epitopes (matrix protein 2 ectodomain (M2e) and CDhelix), and these epitopes were presented on the surface of ferritin in a sequential tandem format. Subcutaneous immunization with 3MCD-f in the absence of adjuvant induces robust humoral and cellular immune responses. These results provide a proof of concept for the 3MCD-f nanovaccine that might be an ideal candidate for future influenza pandemics.

show abstract

Section: Introductionmentioning

confidence: 99%

A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The high baseline titers are the results of previous exposures to the influenza virus or to earlier vaccinations. It has been widely reported that the baseline titers have an effect on the responses to the flu vaccine, with controversial results [14,[33][34][35][36][37][38]. Here, we found that the baseline titer correlates with the response (data not shown).…”

Section: Discussionmentioning

confidence: 44%

Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination

Riccomi,

Trombetta,

Dorrucci

et al. 2024

Preprint

View full text Add to dashboard Cite

A number of studies suggested that influenza vaccination can provide protection against COVID-19 but the underlying mechanisms that could explain this association is still unclear. In this study, the effect of the 2021/2022 seasonal influenza vaccination on the immune response to the booster dose of anti-SARS-CoV-2 vaccination was evaluated in a cohort of healthy individuals. One hundred and thirteen participants were enrolled, and 74 of them with no prior COVID-19 diagnosis or significant co-morbidities were considered for the analysis. Participants received the anti-influenza tetravalent vaccine and the booster dose of the anti-SARS-CoV-2 vaccine or the anti-SARS-CoV-2 vaccine alone. Blood was collected before and 4 weeks after each vaccination and 12 weeks after SARSCoV2 vaccination and analyzed for anti-flu and anti-spike-specific antibody titers and for in vitro influenza and SARS-CoV-2 neutralization capacity. Results indicated an increased reactivity in subjects who received both influenza and SARSCoV2 vaccinations, as compared to those who received only the SARS-CoV-2 vaccine, with sustained anti-spike antibody titers up to 12 weeks post-vaccination. Immune response to influenza vaccine was evaluated and individuals were stratified as high or low responders. High responders showed increased antibody titers against SARSCoV2 vaccine both after 4- and 12-weeks post-vaccination. On the contrary, the individuals classified as low responders were less responsive to the SARS-CoV-2 vaccine. These data indicate that both external stimuli, such as influenza vaccination, and the host's intrinsic ability to respond to stimuli play a role in the response to vaccine.

show abstract

“…The high baseline titers are the results of previous exposures to the influenza virus or to earlier vaccinations. It has been widely reported that the baseline titers have an effect on the responses to the flu vaccine, with controversial results [14,[34][35][36][37][38][39]. Here, we found that the baseline titer correlates with the response.…”

Section: Discussionmentioning

confidence: 44%

Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination

Riccomi,

Trombetta,

Dorrucci

et al. 2024

Vaccines

View full text Add to dashboard Cite

A number of studies have suggested that influenza vaccination can provide protection against COVID-19, but the underlying mechanisms that could explain this association are still unclear. In this study, the effect of the 2021/2022 seasonal influenza vaccination on the immune response to the booster dose of anti-SARS-CoV-2 vaccination was evaluated in a cohort of healthy individuals. A total of 113 participants were enrolled, 74 of whom had no prior COVID-19 diagnosis or significant comorbidities were considered for the analysis. Participants received the anti-influenza tetravalent vaccine and the booster dose of the anti-SARS-CoV-2 vaccine or the anti-SARS-CoV-2 vaccine alone. Blood was collected before and 4 weeks after each vaccination and 12 weeks after SARS-CoV-2 vaccination and analyzed for anti-flu and anti-spike-specific antibody titers and for in vitro influenza and SARS-CoV-2 neutralization capacity. Results indicated an increased reactivity in subjects who received both influenza and SARS-CoV-2 vaccinations compared to those who received only the SARS-CoV-2 vaccine, with sustained anti-spike antibody titers up to 12 weeks post-vaccination. Immune response to the influenza vaccine was evaluated, and individuals were stratified as high or low responders. High responders showed increased antibody titers against the SARS-CoV-2 vaccine both after 4 and 12 weeks post-vaccination. Conversely, individuals classified as low responders were less responsive to the SARS-CoV-2 vaccine. These data indicate that both external stimuli, such as influenza vaccination, and the host’s intrinsic ability to respond to stimuli play a role in the response to the vaccine.

show abstract

Repeated influenza vaccination provides cumulative protection from distinct H3N2 viruses

Cited by 10 publications

References 29 publications

A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice

A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice

Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination

Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination

Contact Info

Product

Resources

About